Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-53

Ellume recalled several mil of tests just weeks prior to expiry date of our raw matieral contract.
As previously mentioned, there was a clear timeline opportunity to have legally secured a way out of the agreement for Ellume.
Since there is no mention of Ellume in the update, it might be the case that the company will source the raw material elsewhere which
would be a major blow to shareholders who pinned so much hope of the relationship.

Ellume's contract with the US army was the reason why ADO's shareprice exploded from 10 to 49 cents, which was always
an unrealistic representation of its revenue outlook, as it was stated on the announcement to only expect modest revenue increases.


Lots of forward looking statements, 135 k in cash receipts is actually ridiculous for a company which launched a COVID RAT in the middle of a pandemic half a year ago.
With this revenue reported, it seems obvious why the rally from 17 to 30 cents was staged prior to the quarterly and surrounding the
webinar some weeks ago.

all IMO